What Researchers Did
Researchers tested the safety of Dexcom G6 continuous glucose monitoring (CGM) transmitters during hyperbaric oxygen therapy (HBOT) by subjecting six devices to 11 pressurization cycles up to 45 feet of seawater.
What They Found
The study found no changes in estimated glucose value generator readings or structural damage to the six Dexcom G6 CGM transmitters after 11 hyperbaric exposures to 45 feet of seawater. This means the transmitters meet the 2018 National Fire Protection Association 99 safety requirements for battery-operated devices allowed for use in a hyperbaric environment.
What This Means for Canadian Patients
For Canadian patients with diabetes who require hyperbaric oxygen therapy, this research suggests that using Dexcom G6 continuous glucose monitors may be safe. Real-time glucose monitoring during HBOT can help manage blood sugar levels, which is crucial for patient safety and treatment effectiveness.
Canadian Relevance
This study covers a Health Canada-recognized indication, as hyperbaric oxygen therapy is used for diabetic foot ulcers, and this research addresses the safety of glucose monitoring for diabetic patients undergoing HBOT.
Study Limitations
This study focused on a specific continuous glucose monitoring device, the Dexcom G6, and a limited number of test cycles.